Increased expression of S100A6 promotes cell proliferation in gastric cancer cells

Abstract

S100A6 is involved in regulating the progression of cancer. S100A6 can regulate the dynamics of cytoskeletal constituents, cell growth and differentiation by interacting with binding or target proteins. The present study investigated whether S100A6 affects cell proliferation in gastric cancer cells by stimulating several downstream factors. Firstly, the expression and localization of S100A6 were investigated using immunohistochemical staining, an immunoelectron microscopy and laser confocal scanning. A ChIP-Chip assay was performed to determine the downstream factors of S100A6 using promoter Chip analysis, including approximately the −800 to +200 regions around the transcription starting point. Polymerase chain reaction analysis was performed to confirm this. It was found that the intensity of S100A6 staining was markedly higher in the cytoplasm and nucleus, and its expression level correlated with that of the Ki67 protein. The overexpression of S100A6 also promoted cell proliferation in AGS and BGC823 cell lines, detected using a Cell Counting-Kit 8 assay. In cells overexpressing S100A6, the expression levels of interleukin (IL)-8, cyclin-dependent kinase (CDK)5, CDK4, minichromosome maintenance complex component 7 (MCM7) and B-cell lymphoma 2 (Bcl2) were noticeably increased. In conclusion, the increased expression of S100A6 promoted cell proliferation by regulating the expression levels of IL-8, CDK5, CDK4, MCM7 and Bcl2 in gastric cancer cells.

S100A6 represses Calu‐6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis

“… 13 In gastric cancer, Wang et al found S100A6 had a remarkable increased expression in patients' tissues, and this overexpression had a clear correlation with high invasive cell behaviours, including positive lymph node involvement as well as vascular invasion. 14 Similar conclusions were also reached in pancreatic cancer and human nasopharyngeal carcinoma. 15 , 16 However, S100A6, along with another member‐S100A1, was considered to be associated with better prognosis in breast cancer patients.…”

Calcyclin (S100A6) Attenuates Inflammatory Response and Mediates Apoptosis of Chondrocytes in Osteoarthritis via the PI3K/AKT Pathway

“…Thus, it is important to detect the potential biomarkers or novel therapy of osteoarthritis. According to present studies, S100A6 was involved in cell survival and apoptosis in many cancer diseases, such as breast cancer 21 , malignant thyroid neoplasm 22 , gastric cancer 10 . However, owing to the deficiency of relevant researches about S100A6 roles in osteoarthritis, its biological functions and research value remain to be fully clarified.…”

“…The roles of S100A6 were widely discussed in the literature. Many studies have found the expression level of S100A6 associated closely with the physiological process of some cancer diseases and affect their apoptosis or proliferation activities, such as hepatocellular carcinoma, cervical cancer, and gastric cancer 8–10 . For other types of diseases, take myocardial infarction for example, researchers discovered the over‐expression of S100A6 inhibited the cell apoptosis and significantly improved the infarct size in vitro 11 .…”

Identification of differentially expressed proteins in the gastric mucosal atypical hyperplasia tissue microenvironment

“…In total, 99 proteins (G/N>1.5) were identified to be upregulated and 66 proteins (G/N<0.667) were identified to be downregulated in the GMAH mesenchyma. The expression levels of the S100A6 and SOD3 proteins were different in the mesenchyma of the NGM and GMAH tissues, and were associated with tumorigenesis in previous studies ( 9 , 10 ). Fig.…”